Trevena Inc is a clinical stage biopharmaceutical company involved in the discovery and development of G-protein coupled receptors (GPCR) biased ligands. The Company's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena’s pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson’s disease.

Type
Public
HQ
King of Prussia, US
Founded
2008
Size (employees)
72 (est)
Trevena was founded in 2008 and is headquartered in King of Prussia, US
Report incorrect company information

Key People/Management at Trevena

Maxine Gowen Ph.D

Maxine Gowen Ph.D

President and Chief Executive Officer
Carrie L. Bourdow

Carrie L. Bourdow

Executive Vice President and Chief Operating Officer
David P. Geoghegan

David P. Geoghegan

Senior Vice President, Operations
John M. Limongelli Esq

John M. Limongelli Esq

Senior Vice President, General Counsel and Chief Administrative Officer

Trevena Office Locations

Trevena has an office in King of Prussia
King of Prussia, US (HQ)
1018 West 8th Avenue
Show all (1)
Report incorrect company information

Trevena Financials and Metrics

Trevena Financials

Trevena's revenue was reported to be $3.75 m in FY, 2016 which is a 40% decrease from the previous period.
USD

EBIT (Q1, 2018)

(9.7 m)

Market capitalization (15-May-2018)

132.5 m

Closing share price (15-May-2018)

2

Cash (31-Mar-2018)

18.1 m
Trevena's current market capitalization is $132.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

6.3 m3.8 m

Revenue growth, %

(40%)

Net Income

(49.7 m)(50.5 m)(103 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(20.9 m)(36.4 m)(12.9 m)(24.4 m)(35.1 m)(17.8 m)(37 m)(66.9 m)(20.7 m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

36.2 m46.8 m24.3 m16.6 m

Accounts Receivable

4.1 m

Inventories

669.2 k1.9 m1.8 m

Current Assets

107.6 m174.5 m112.4 m67.5 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

81.6 m72.2 m29.1 m43.7 m39 m34.5 m36.8 m25.2 m18.7 m14 m18.1 m

Current Assets

84.2 m73.1 m102.5 m107.3 m170 m166 m147.6 m121.3 m100.8 m87.7 m63.4 m

PP&E

392.3 k594 k590.2 k609.3 k601.5 k823.5 k807.4 k745.3 k1.1 m2.9 m3.8 m

Total Assets

84.7 m74 m103.2 m108 m170.7 m166.9 m148.6 m122.1 m103.1 m92 m68.6 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(49.7 m)(50.5 m)(103 m)(71.9 m)

Depreciation and Amortization

239.4 k207.9 k246 k490 k

Inventories

(2.9 m)(2.8 m)

Accounts Payable

4.2 m2.8 m7.1 m(8.4 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(20.9 m)(36.4 m)(12.9 m)(24.4 m)(35.1 m)(17.8 m)(37 m)(66.9 m)(20.7 m)(41.1 m)(9 m)

Depreciation and Amortization

142.1 k184.9 k52.5 k104.5 k155.3 k57.5 k118.5 k180 k79 k158 k171 k

Accounts Payable

(2.4 m)(1.3 m)(1.9 m)(2.2 m)(1.1 m)620.8 k(9.9 m)

Cash From Operating Activities

(15.8 m)(26.7 m)(6 m)(16.3 m)(28.2 m)(20.6 m)(39.2 m)(63.9 m)(29.5 m)(47.7 m)(10.4 m)
USDY, 2018

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information